Parathyroid Hormone (1-34), bovine |
| Catalog No.GP10106 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 12583-68-5
Sample solution is provided at 25 µL, 10mM.
GlpBio Products Cited In Reputable Papers
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Product Documents
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Protocol
| Cell experiment [1]: | |
|
Cell lines |
Mouse primary bone marrow stromal cells (BMSCs). |
|
Preparation method |
Dissolved in acetic acid [1]. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reaction Conditions |
100 ng/ml; 2 h. |
|
Applications |
bPTH(1-34) increases RANKL mRNA levels and inhibits osteoprotegerin (OPG) gene expression. bPTH(1-34) also increases the amount of TRACP+ cells. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice. |
|
Dosage form |
80 μg/kg/day; 7 or 14 days; injected subcutaneously. |
|
Applications |
PTH(1-34) significantly increases the percentage of TN/CD115(+) CD117(high) and TN/CD115(+) CD117(int) cells in bone marrow on day 7. However, PTH(1-34) decreases the amount of TN/CD115(+) CD117(low) cells by 39% on day 7. PTH increases receptor activator of NF-kB ligand (RANKL)- and macrophage colony-stimulating factor (M-CSF)-stimulated in vitro osteoclastogenesis and bone resorption in TN/CD115+ cells. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Huang JC, Sakata T, Pfleger LL, et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004, 19(2): 235-244. [2]. Jacome-Galarza CE, Lee SK, Lorenzo JA, et al. Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic progenitors in the bone marrow. J Bone Miner Res, 2011, 26(6): 1207-1216. | |
| Cas No. | 12583-68-5 | SDF | |
| Formula | C183H288N54O50S2 | M.Wt | 4108.71 |
| Solubility | ≥410.9mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Complete Stock Solution Preparation Table
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2434 mL | 1.2169 mL | 2.4339 mL |
| 5 mM | 0.0487 mL | 0.2434 mL | 0.4868 mL |
| 10 mM | 0.0243 mL | 0.1217 mL | 0.2434 mL |
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Related Products
- GP10037 Large T antigen - rhesus polyomavirus 560-568
- GP10058 Fusion glycoprotein (92-106) [Human respiratory syncytial virus]
- GP10116 Immunoglobulin M heavy chain (IGHM) fragment [Homo sapiens]
- GP10137 ANP (1-11), rat
- GP10107 Gap 26
- GP10045 Angiotensin 1/2 (2-7)
- GP10029 Interleukin II (60-70)
- GP10031 Leptin (116-130) amide (mouse)
- GP10025 Angiotensin 1/2 (1-9)
- GP10042 Rhodopsin peptide
- GP10145 signal transducer and activator of transcription 6 fragment
- GP10015 alpha-1 antitrypsin fragment
- GP10161 Proteinase K
- GP10083 Beta-Amyloid (1-11)
- GP10010 COG 133
- GP10007 Cytochrome c fragment (93-108)
- GP10055 hemagglutinin precursor (114-122) amide [Influenza A virus]
Avis
Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *